Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perrigo CoPRGO -3.53%44 3-1 Month Momentum % is -18.82% as of Jul. 24, 2026. GuruFocus rates PRGO with a GF Score™ of 44/100 and a GF Value™ of $24.92 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,025 Drug Manufacturers companies, Perrigo Co ranks worse than 73.76% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-24), Perrigo Co's 3-1 Month Momentum % is -18.82%.
The industry rank for Perrigo Co's 3-1 Month Momentum % or its related term are showing as below:
PRGO's 3-1 Month Momentum % is ranked worse than 73.76% of 1025
companies
in the Drug Manufacturers industry
Industry Median: -7.9
vs PRGO: -18.82
Perrigo Co (NYSE:PRGO) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Perrigo Co 3-1 Month Momentum % Related Terms
PRGO vs XERS, PAHC, ALVO: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Perrigo Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perrigo Co 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perrigo Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Perrigo Co's 3-1 Month Momentum % falls into.
Perrigo Co (NYSE:PRGO) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perrigo Co (PRGO) has a 3-1 Month Momentum % of -18.82% as of Jul. 24, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Perrigo Co and its competitors. According to the industry distribution chart, Perrigo Co ranks #756 out of 1025 companies in the Drug Manufacturers industry, placing it in the top 73.8%.
Is Perrigo Co's 3-1 Month Momentum % too high?
Perrigo Co's current 3-1 Month Momentum % is -18.82%. Based on the distribution chart, Perrigo Co ranks #756 out of 1025 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Perrigo Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Perrigo Co's 3-1 Month Momentum % compare to XERS and PAHC?
According to the Drug Manufacturers industry distribution chart, Perrigo Co ranks #756 out of 1025 companies for 3-1 Month Momentum %. This places Perrigo Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Perrigo Co and its competitors. Perrigo Co's current 3-1 Month Momentum % is -18.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perrigo Co stock overvalued right now?
Based on GuruFocus' analysis, Perrigo Co (PRGO) is currently considered Possible Value Trap. The stock's GF Value™ is $24.92, compared to a current price of $10.10 — trading 59.5% below its estimated fair value. The current 3-1 Month Momentum % is -18.82%. Perrigo Co's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Perrigo Co (PRGO), the current 3-1 Month Momentum % is -18.82% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perrigo Co (PRGO) Overvalued in 2026?
Based on GuruFocus' analysis, Perrigo Co stock appears to be undervalued.
The current stock price of $10.10 is trading 59.5% below its estimated GF Value™ of $24.92.
GuruFocus considers Perrigo Co to be Possible Value Trap.
Key valuation signals for PRGO:
3-1 Month Momentum %: -18.82%
GF Value™: $24.92 vs. price of $10.10 (59.5% below fair value)
No single metric tells the full story. See the PRGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
44GF Score
Get the complete analysis for PRGO
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRGO has been successfully added to your 
